Search Clinical Trials in the European Union

6-12 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
141-160 of 397 trials

Lung Transplant Rejection: Stem Cell Treatment Study

We are studying the safety of a new stem cell treatment for patients experiencing chronic rejection after a lung transplant. This trial aims to see if it can help slow down the progression of their condition.

Bronchiolitis Obliterans Syndrome (BOS)6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicinePulmonology

Cardiovascular Disease: Gene Analysis for Statin Treatment

We are studying whether a gene analysis strategy can help people at risk of cardiovascular disease better tolerate statins and reduce side effects. This trial compares this approach to standard treatment methods.

Patients at Risk of Cardiovascular Disease6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

HIV-1 Treatment: Bictegravir/Lenacapavir for Kids and Teens

We are studying a new combination medication for children and adolescents with HIV-1 to see how well it works and how safe it is. The trial will also check if young patients find the medication easy to take.

HIV-1 Infection6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Schizophrenia Spectrum Disorders: Oxytocin Treatment Study

We are investigating whether intranasal oxytocin can enhance social skills and functioning in individuals with schizophrenia spectrum disorders. This study compares oxytocin to a placebo alongside standard psychosocial treatment.

Schizophrenia6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Type 1 Diabetes: Sotagliflozin for Kidney Health

We are investigating whether sotagliflozin can improve kidney oxygen levels in people with type 1 diabetes and chronic kidney disease. This study aims to understand its effects over three months of treatment.

Type 1 Diabetes with Kidney Complications6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyInternal MedicineNephrology

Melanoma: [68Ga]Ga-FAPI PET/CT Imaging Study

We are testing a new imaging method to see how well immune checkpoint inhibitor therapy works in patients with advanced melanoma. This study aims to improve response evaluation during treatment.

Malignant Melanoma6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesDermatologyOncology

Cholesterol Management: Rosuvastatin 10 mg

We are examining whether a new formulation of Rosuvastatin 10 mg works the same as the current version for managing cholesterol levels. This study is for individuals who need cholesterol-lowering treatment.

Healthy Volunteers6-12 monthsSafety phase (I)CardiologyInternal Medicine

Sepsis Treatment: Meropenem vs. Piperacillin/Tazobactam

We are comparing two antibiotics to see which one may help critically ill adults with sepsis survive better and improve their health outcomes.

Septic ShockSepsis6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Burning Mouth Syndrome: Clonazepam Treatment Study

We are exploring how a topical treatment with clonazepam affects pain and other symptoms in people with burning mouth syndrome. The study will also look at patient preferences and experiences with the treatment over time.

Burning Mouth Syndrome6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyPsychiatry

Childhood Leukemia: Inotuzumab Ozogamicin vs. ALLR3

We are studying whether Inotuzumab Ozogamicin works better than standard treatment for children with high-risk first relapse B-cell leukemia. The trial focuses on safety and long-term effectiveness in young patients.

Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics

Acetyl-L-Carnitine for ALS Treatment

We are studying whether acetyl-L-carnitine can help slow down the progression of ALS and improve quality of life. Participants will receive different doses to see which is most effective and safe.

Amyotrophic Lateral Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesNeurology

Early Breast Cancer: Abemaciclib and Giredestrant Study

We are investigating the safety and effectiveness of two medications for patients with early-stage, hormone-sensitive breast cancer before surgery. The goal is to see if this treatment can help reduce tumor size and improve outcomes.

Early Breast Cancer (ER-positive, HER2-negative)6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Prurigo Nodularis: Barzolvolimab Study

We are testing a new medication, barzolvolimab, for people with prurigo nodularis to see if it helps reduce itching and improve skin lesions. The study will also look at the safety of this treatment and its effects on quality of life.

Prurigo Nodularis6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesAllergologyDermatology

Uveal Melanoma: Tebentafusp Treatment Study

We are studying whether the drug tebentafusp can help prevent cancer recurrence in patients with high-risk uveal melanoma after surgery or radiation. This trial also looks at the safety of the treatment compared to observation.

Uveal Melanoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncologyOphthalmology

Pneumococcal Vaccine Response: Age and HIV Impact

We are studying how age and HIV infection affect the immune response to pneumococcal vaccination. This research aims to improve vaccine effectiveness for different populations.

HIV Infection6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Carvedilol vs. Flecainide for Ventricular Arrhythmias

We are comparing two medications to see which one better reduces abnormal heartbeats in people with idiopathic ventricular arrhythmias. The study also looks at how these treatments affect quality of life and any side effects.

Ventricular ExtrasystolesMonomorphic Ventricular TachycardiaIdiopathic Ventricular Arrhythmias6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiology

Type 1 Diabetes: LY3938577 Study

We are assessing a new medication to see how safe it is and how it works in people with type 1 diabetes and healthy participants. This study may help us understand its potential benefits for managing diabetes.

Type 1 Diabetes6-12 monthsSafety phase (I)DiabetologyEndocrinology

Mixed Dyslipidemia: RBD5044 Treatment Study

We are testing a new medication, RBD5044, for people with mixed dyslipidemia to see if it improves cholesterol and lipid levels. The study also looks at the safety of this treatment when given as injections.

Mixed Dyslipidemia6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCardiologyInternal Medicine

Pancreatic Cancer: Organoid-Based Treatment Selection

We are studying whether lab-grown mini-tumors can help choose better post-surgery treatments for patients with resectable pancreatic cancer. This may improve recovery and outcomes after surgery.

Pancreatic Ductal Adenocarcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Interstitial Lung Disease: Rituximab and Mycophenolate Combination

We are studying a combination of rituximab and mycophenolate mofetil for patients with interstitial lung disease related to systemic sclerosis. The goal is to see if this treatment improves lung function and overall health compared to a placebo.

Lung Involvement in Systemic Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesPulmonologyRheumatology